Cereno Scientific to present candidate drug CS585 preclinical data at EHA 2022 – the premier medical congress for hematology

Cereno Scientific (XSAT: CRNO B) today announced that an abstract on preclinical drug candidate CS585 has been accepted as an oral presentation by the Scientific Program Committee at the European Hematology Association (EHA) 2022 Hybrid Congress in Vienna, Austria, on June 9-12, 2022. The abstract: “CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding” will be presented by Dr. Michael Holinstat, lead of Cereno’s preclinical development programs at University of Michigan and Director of Translational Research at Cereno.

“It is very exciting that we for the first time have been able to show that our candidate drug CS585, a novel prostacyclin receptor agonist with favourable characteristics of stability, potency and selectivity, in preclinical studies is able to inhibit platelet activation and thrombosis without an increased risk of bleeding. These findings are significant as there is a strong unmet medical need for new drugs providing prevention of thrombosis without increased risk of bleeding as available anti-thrombotic drugs do pose an increased risk of bleeding for patients,” said Sten R. Sörensen, CEO at Cereno.

The abstract titled “CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding”, was authored by Sylviane Lambert, Reheman Adili, Pooja Yalavarthi and Nicole Rhoads at Pharmacology, University of Michigan Medical School; Björn Dahlöf at Cereno Scientific and Institute of Medicine, University of Gothenburg; Andrew White at Medicinal Chemistry, University of Michigan Medical School; Niklas Bergh at Cereno Scientific and Institute of Medicine, University of Gothenburg; Michael Holinstat at Pharmacology and Internal Medicine, University of Michigan Medical School. The abstract has been selected to be presented as an oral presentation by Dr. Michael Holinstat.

The EHA2022 Hybrid Congress is organized by the European Hematology Association (EHA). The congress specializes in hematology and its subspecialties and, in particular, cutting-edge evidence-based approaches to diagnosis and treatment, highly anticipated clinical and translational research data, and newest developments in innovative techniques, diagnostic tools, and risk-assessment strategies.

The abstract will be published on May 12, 2022, at 16:00 CEST, in the online Abstract Book, a supplement of HemaSphere (EHA’s official journal), the EHA Library and the Congress platform.

Details on the oral presentation at EHA2022:

Title: CS585 IS A FIRST-IN-CLASS COMPOUND TARGETING THE IP RECEPTOR FOR PREVENTION OF THROMBOSIS WITHOUT INCREASED RISK OF BLEEDING

Session Title: Novel aspects of hemostasis and therapeutic interventions

Session date and time: Sunday, June 12 11:30 - 12:45

Session room: Hall Lehar 3-4

Final Abstract Code:  S298

Presenting Author: Michael Holinstat

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with anti-inflammatory, anti-fibrotic, reverse-remodeling, pressure-reducing and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Targeted at treating cardiovascular disease, drug candidate CS585 is a stable, selective, and potent IP (prostacyclin) receptor agonist and drug candidate CS014 is an HDAC inhibitor with epigenetic effects. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.